| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aba4dde70a777e13db59102161fc1743 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2019-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8c0ae7925de0d0a624103ab98dcf0ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eb3d0c60c916f9f3a6c31efc825d477
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab96c7cfcf1fae4aa38fd637beb6b05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_264f23fb1133f6189ea91eae9b678089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15a944c0fa56c560d47e1c5eab247e9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48f81f9e0ebec251f4845542a1b8e936 |
| publicationDate |
2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210042335-A |
| titleOfInvention |
Methods of inhibiting hepatitis B virus replication and secretion of hepatitis B virus surface antigens |
| abstract |
Pharmaceutical compositions for use in treating hepatitis B virus (HBV) infection comprise an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating a hepatitis B virus infection comprises administering an antibody against CD11b to a subject in need thereof. Anti-CD11b antibody binding to CD11b can trigger an immunostimulatory response, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMC); Suppressed levels of hepatitis B surface antigen (HBsAg) and HBV DNA in blood; And accelerated clearance of HBV from the liver. |
| priorityDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |